February 24, 2023 07:00 AM EST

Nektar’s latest PhII flop threatens to unravel $400M-plus deal with Eli Lilly

Amber Tong

Eli Lilly is slamming the Phase III door for the lead program out of its six-year-old pact with Nektar Therapeutics, after their partnered autoimmune drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nektar’s latest PhII flop threatens to unravel $400M-plus deal with Eli Lilly

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Stem cell startup spun out of George Church’s lab raises $75M

Breaking down silos with a new quantitative approach to drug development

Nek­tar’s lat­est PhII flop threat­ens to un­rav­el $400M-plus deal with Eli Lil­ly

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Nektar’s latest PhII flop threatens to unravel $400M-plus deal with Eli Lilly